Bicara Therapeutics (NASDAQ:BCAX) Trading Down 3.5% – What’s Next?

Bicara Therapeutics Inc. (NASDAQ:BCAX)’s stock price fell 3.5% during trading on Wednesday . The stock traded as low as $21.56 and last traded at $21.76. 80,122 shares changed hands during trading, a decline of 77% from the average session volume of 349,583 shares. The stock had previously closed at $22.55.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Stifel Nicolaus initiated coverage on Bicara Therapeutics in a report on Tuesday. They issued a “buy” rating and a $47.00 price target on the stock. TD Cowen assumed coverage on shares of Bicara Therapeutics in a report on Tuesday. They issued a “buy” rating on the stock. Morgan Stanley started coverage on shares of Bicara Therapeutics in a report on Tuesday. They set an “overweight” rating and a $35.00 price objective for the company. Finally, Cantor Fitzgerald assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday. They issued an “overweight” rating on the stock.

Bicara Therapeutics Trading Down 10.0 %

Insider Buying and Selling at Bicara Therapeutics

In other Bicara Therapeutics news, Director Ra Capital Management, L.P. acquired 1,833,000 shares of Bicara Therapeutics stock in a transaction that occurred on Monday, September 16th. The stock was bought at an average price of $18.00 per share, with a total value of $32,994,000.00. Following the completion of the purchase, the director now directly owns 4,303,418 shares of the company’s stock, valued at approximately $77,461,524. This represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Bicara Therapeutics news, major shareholder James E. Flynn acquired 70,000 shares of the stock in a transaction dated Tuesday, September 17th. The stock was purchased at an average price of $18.00 per share, with a total value of $1,260,000.00. Following the transaction, the insider now directly owns 897,587 shares of the company’s stock, valued at $16,156,566. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Ra Capital Management, L.P. bought 1,833,000 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $32,994,000.00. Following the completion of the purchase, the director now owns 4,303,418 shares in the company, valued at $77,461,524. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.